Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;26(5):347-355.
doi: 10.1007/s11916-022-01034-w. Epub 2022 Feb 26.

Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments

Chia-Kuang Tsai  1 , Chia-Lin Tsai  1 , Guan-Yu Lin  1 , Fu-Chi Yang  2 , Shuu-Jiun Wang  3   4   5
Affiliations
Review

Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments

Chia-Kuang Tsai et al. Curr Pain Headache Rep. 2022 May.

Abstract

Purpose of review: This review provides an update on sex differences in chronic migraine (CM), with a focus on clinical characteristics, pathophysiology, and treatments.

Recent findings: Approximately 6.8-7.8% of all migraineurs have CM, with an estimated prevalence of 1.4-2.2% in the general population. The economic burden caused by CM, including medical costs and lost working ability, is threefold higher than that caused by episodic migraine (EM). Notably, the prevalence of migraine is affected by age and sex. Female migraineurs with CM experience higher levels of headache-related disability, including longer headache duration, higher frequency of attacks, and more severely impacted efficiency at work. Sex hormones, including estrogen, testosterone, and progesterone, contribute to the sexually dimorphic characteristics and prevalence of migraine in men and women. Recent neuroimaging studies have indicated that migraine may have a greater impact and cause greater dysfunction in the organization of resting-state functional networks in women. Accumulating evidence suggests that topiramate, Onabotulinumtoxin A and calcitonin gene-related peptide (CGRP) monoclonal antibodies are effective as the preventative treatments for CM. Recent evidence highlights a divergence in the characteristics of CM between male and female populations. The data comparing the treatment response for CM regarding sex are lacking.

Keywords: Chronic migraine; Gender; Management; Pathophysiology; Sex difference.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808. https://doi.org/10.1177/0333102413485658 .
    1. Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33:171–81. https://doi.org/10.1177/0333102412468668 . - DOI - PubMed
    1. Tang CH, Chen YC, Ng K, Wang SJ. A retrospective matched case-control study on medical costs of refractory migraine in Taiwan. Headache. 2013;53:526–39. https://doi.org/10.1111/head.12039 . - DOI - PubMed
    1. Lewis DW. Pediatric migraine. Pediatr Rev. 2007;28:43–53. https://doi.org/10.1542/pir.28-2-43 . - DOI - PubMed
    1. Macgregor EA, Rosenberg JD, Kurth T. Sex-related differences in epidemiological and clinic-based headache studies. Headache. 2011;51:843–59. https://doi.org/10.1111/j.1526-4610.2011.01904.x . - DOI - PubMed

LinkOut - more resources